News | October 31, 2025
Merck’s Capvaxive shows strong momentum amid industry vaccine decline
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Subscribe To Our Newsletter & Stay Updated
